Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT study of single-dose cedazuridine in healthy volunteers
NL-OMON50873Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of cedazuridine (4 arms), sponsored by Astex Pharmaceuticals. Primary endpoint: Effect of single therapeutic and supratherapeutic dose of cedazuridine on QTcF. Started Jun 2021; status: completed.
02
Drugs
cedazuridine
Beyond the preview
Go deeper on NL-OMON50873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50873.